Active	Status	Sponsor type	Region	Phase	Filter
9 Active 1 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schwartzmann, Pedro V
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial Feb 2024 - Dec 2024 : Data from SUMMIT trial in participants with heart failure with preserved ejection fraction and obesity	Completed	3	731	US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)	07/24	07/24
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)	Active, not recruiting	2	456	Europe, Canada, Japan, US, RoW	LY3540378, Placebo	Eli Lilly and Company	Heart Failure, Heart Failure With Preserved Ejection Fraction	01/25	01/25
Ichijo, Takamasa
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
Sakai, Tsuyoshi
BIO|STREAM HF, NCT03366545: Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices	Recruiting	N/A	3000	Europe, Japan, RoW	Cardiac Resynchronization Therapy (CRT)	Biotronik SE & Co. KG	Heart Failure	03/26	03/26
Silva, Raphael Ap
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)	Active, not recruiting	2	456	Europe, Canada, Japan, US, RoW	LY3540378, Placebo	Eli Lilly and Company	Heart Failure, Heart Failure With Preserved Ejection Fraction	01/25	01/25
Omasa, Kosei
J-NEURO, NCT06776549: Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest	Recruiting	N/A	468	Japan	Temperature control	Kagawa University	Out-of-hospital Cardiac Arrest (OHCA), ECMO Treatment, Temperature, Post Cardiac Arrest Syndrome	12/27	12/28